Sign In

Login

Password

Forgot Password ? Sign Up

Monoklonale Gammopathie (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Monoklonale Gammopathie" in German language version.

refsWebsite
Global rank German rank
23doi.org
2nd place
3rd place
23nih.gov
4th place
7th place
1ajkd.org
low place
low place
1gekid.de
low place
low place

ajkd.org

doi.org

  • GP Mead et al.: Serum free light chains for monitoring multiple myeloma. In: Br J Hematol. 126. Jahrgang, Nr. 3, 29. März 2004, S. 348–354, doi:10.1111/j.1365-2141.2004.05045.x, PMID 15257706.
  • N Leung et al.: Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. In: Blood. 120. Jahrgang, Nr. 22, 9. Oktober 2012, S. 4292–4295, doi:10.1182/blood-2012-07-445304, PMID 23047823.
  • RA. Kyle et al.: Monoclonal gammopathy of undetermined significance. In: Br J Haematol. 134. Jahrgang, Nr. 6, 2006, S. 573–589, doi:10.1111/j.1365-2141, PMID 16938117.
  • RA. Kyle et al.: Prevalence of monoclonal gammopathy of undetermined significance. In: N Engl J Med. 354. Jahrgang, Nr. 13, 2006, S. 1362–1369, doi:10.1056/NEJMoa054494, PMID 16571879.
  • N van de Donk et al.: The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. In: Haematologica. 99. Jahrgang, Nr. 6, 21. März 2014, S. 984–96, doi:10.3324/haematol.2013.100552, PMID 23224402, PMC 4040895 (freier Volltext).
  • GJ Morgan et al.: The genetic architecture of multiple myeloma. In: Nat Rev Cancer. 12. Jahrgang, Nr. 5, Mai 2012, S. 335-48, doi:10.1038/nrc3257, PMID 22495321.
  • M Chesi et al.: Advances in the pathogenesis and diagnosis of multiple myeloma. In: Int Jnl Lab Hem. 2015, S. 108–114, doi:10.1111/ijlh.12360, PMID 25976968.
  • R Fonseca et al.: International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. In: Leukemia. 23. Jahrgang, Nr. 12, Dezember 2009, S. 2210-21, doi:10.1038/leu.2009.174, PMID 19798094, PMC 2964268 (freier Volltext).
  • NC Munshi et al.: Guidelines for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. In: Blood. 117. Jahrgang, Nr. 18, Mai 2011, S. 4696–4700, doi:10.1182/blood-2010-10-300970, PMID 21292777, PMC 3293763 (freier Volltext).
  • A Zingone et al.: Pathogenesis of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Progression to Multiple Myeloma. In: Semin Hematol. 48. Jahrgang, Nr. 1, 1. Januar 2012, S. 4–12, doi:10.1053/j.seminhematol.2010.11.003, PMID 21232653, PMC 3040450 (freier Volltext).
  • SV Rajkumar et al.: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. In: Lancet. 15. Jahrgang, Nr. 12, 15. November 2014, S. e538–48, doi:10.1016/s1470-2045(14)70442-5, PMID 25439696.
  • A Dispenzieri et al.: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. In: Leukemia. 23. Jahrgang, Nr. 2, Februar 2009, S. 215–224, doi:10.1038/leu.2008.307, PMID 19020545.
  • T Golombick et al.: Prevalence of monoclonal gammopathy of undetermined significance/myeloma in patients with acute osteoporotic vertebral fractures. In: Acta Haematol. 120. Jahrgang, Nr. 2, 14. Oktober 2008, S. 87–90, doi:10.1159/000162282, PMID 18852483.
  • N Steiner et al.: Are neurological complications of monoclonal gammopathy of undetermined significance underestimated? In: Oncotarget. 8. Jahrgang, Nr. 3, 10. Dezember 2016, S. 5081–5091, doi:10.18632/oncotarget.13861, PMID 27974705, PMC 5354894 (freier Volltext).
  • SM Ansell et al.: Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. In: Mayo Clin Proc. 85. Jahrgang, Nr. 9, September 2010, S. 824–833, doi:10.4065/mcp.2010.0304, PMID 20702770, PMC 2931618 (freier Volltext).
  • RG Owen et al.: Guidelines on the diagnosis and management of Waldenstrom macroglobulinaemia. In: Br J Hematol. 165. Jahrgang, Nr. 3, Mai 2014, S. 316–333, doi:10.1111/bjh.12760, PMID 24528152.
  • J Gillmore et al.: Guidelines on the diagnosis and investigation of AL amyloidosis. In: Br J Hematol. 168. Jahrgang, Nr. 2, 14. Oktober 2014, S. 207-18, doi:10.1111/bjh.13156, PMID 25312307.
  • SH Nasr et al.: Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. In: Clin J Am Soc Nephrol. 7. Jahrgang, Nr. 2, 14. Dezember 2011, S. 231-9, doi:10.2215/CJN.08640811, PMID 23047823.
  • Mateos & González-Calle: Smoldering Multiple Myeloma: Who and When to Treat. In: Clin Lymphoma Myeloma Leuk. 17. Jahrgang, Nr. 11, November 2017, S. 716–722, doi:10.1016/j.clml.2017.06.022, PMID 28709797.
  • MA Bärtsch et al.: Aktuelle Aspekte bei der Diagnostik und Therapie des Plasmazellmyeloms. In: Dtsch Med Wochenschr. 142. Jahrgang, Nr. 11, 2017, S. 800–804, doi:10.1055/s-0043-100295.
  • JP Bridoux et al.: How I treat monoclonal gammopathy of renal significance (MGRS). In: Blood. 122. Jahrgang, Nr. 22, 9. Oktober 2013, S. 3583–3590, doi:10.1182/blood-2013-05-495929, PMID 24108460.
  • MA Dimopoulos et al.: Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus. In: Blood. 124. Jahrgang, Nr. 9, 17. Juli 2014, S. 1404-11, doi:10.1182/blood-2014-03-565135, PMID 4148763.
  • MA Gertz et al.: Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. In: Am J Hematol. 91. Jahrgang, Nr. 9, 17. August 2016, S. 947-56, doi:10.1002/ajh.24433, PMID 27527836.

gekid.de

nih.gov

ncbi.nlm.nih.gov

  • GP Mead et al.: Serum free light chains for monitoring multiple myeloma. In: Br J Hematol. 126. Jahrgang, Nr. 3, 29. März 2004, S. 348–354, doi:10.1111/j.1365-2141.2004.05045.x, PMID 15257706.
  • The International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. In: Br J Hematol. 121. Jahrgang, Nr. 5, 2. September 2002, S. 749–757, PMID 12780789.
  • N Leung et al.: Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. In: Blood. 120. Jahrgang, Nr. 22, 9. Oktober 2012, S. 4292–4295, doi:10.1182/blood-2012-07-445304, PMID 23047823.
  • RA. Kyle et al.: Monoclonal gammopathy of undetermined significance. In: Br J Haematol. 134. Jahrgang, Nr. 6, 2006, S. 573–589, doi:10.1111/j.1365-2141, PMID 16938117.
  • RA. Kyle et al.: Prevalence of monoclonal gammopathy of undetermined significance. In: N Engl J Med. 354. Jahrgang, Nr. 13, 2006, S. 1362–1369, doi:10.1056/NEJMoa054494, PMID 16571879.
  • N van de Donk et al.: The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. In: Haematologica. 99. Jahrgang, Nr. 6, 21. März 2014, S. 984–96, doi:10.3324/haematol.2013.100552, PMID 23224402, PMC 4040895 (freier Volltext).
  • GJ Morgan et al.: The genetic architecture of multiple myeloma. In: Nat Rev Cancer. 12. Jahrgang, Nr. 5, Mai 2012, S. 335-48, doi:10.1038/nrc3257, PMID 22495321.
  • M Chesi et al.: Advances in the pathogenesis and diagnosis of multiple myeloma. In: Int Jnl Lab Hem. 2015, S. 108–114, doi:10.1111/ijlh.12360, PMID 25976968.
  • R Fonseca et al.: International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. In: Leukemia. 23. Jahrgang, Nr. 12, Dezember 2009, S. 2210-21, doi:10.1038/leu.2009.174, PMID 19798094, PMC 2964268 (freier Volltext).
  • NC Munshi et al.: Guidelines for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. In: Blood. 117. Jahrgang, Nr. 18, Mai 2011, S. 4696–4700, doi:10.1182/blood-2010-10-300970, PMID 21292777, PMC 3293763 (freier Volltext).
  • A Zingone et al.: Pathogenesis of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Progression to Multiple Myeloma. In: Semin Hematol. 48. Jahrgang, Nr. 1, 1. Januar 2012, S. 4–12, doi:10.1053/j.seminhematol.2010.11.003, PMID 21232653, PMC 3040450 (freier Volltext).
  • SV Rajkumar et al.: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. In: Lancet. 15. Jahrgang, Nr. 12, 15. November 2014, S. e538–48, doi:10.1016/s1470-2045(14)70442-5, PMID 25439696.
  • A Dispenzieri et al.: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. In: Leukemia. 23. Jahrgang, Nr. 2, Februar 2009, S. 215–224, doi:10.1038/leu.2008.307, PMID 19020545.
  • T Golombick et al.: Prevalence of monoclonal gammopathy of undetermined significance/myeloma in patients with acute osteoporotic vertebral fractures. In: Acta Haematol. 120. Jahrgang, Nr. 2, 14. Oktober 2008, S. 87–90, doi:10.1159/000162282, PMID 18852483.
  • N Steiner et al.: Are neurological complications of monoclonal gammopathy of undetermined significance underestimated? In: Oncotarget. 8. Jahrgang, Nr. 3, 10. Dezember 2016, S. 5081–5091, doi:10.18632/oncotarget.13861, PMID 27974705, PMC 5354894 (freier Volltext).
  • SM Ansell et al.: Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. In: Mayo Clin Proc. 85. Jahrgang, Nr. 9, September 2010, S. 824–833, doi:10.4065/mcp.2010.0304, PMID 20702770, PMC 2931618 (freier Volltext).
  • RG Owen et al.: Guidelines on the diagnosis and management of Waldenstrom macroglobulinaemia. In: Br J Hematol. 165. Jahrgang, Nr. 3, Mai 2014, S. 316–333, doi:10.1111/bjh.12760, PMID 24528152.
  • J Gillmore et al.: Guidelines on the diagnosis and investigation of AL amyloidosis. In: Br J Hematol. 168. Jahrgang, Nr. 2, 14. Oktober 2014, S. 207-18, doi:10.1111/bjh.13156, PMID 25312307.
  • SH Nasr et al.: Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. In: Clin J Am Soc Nephrol. 7. Jahrgang, Nr. 2, 14. Dezember 2011, S. 231-9, doi:10.2215/CJN.08640811, PMID 23047823.
  • Mateos & González-Calle: Smoldering Multiple Myeloma: Who and When to Treat. In: Clin Lymphoma Myeloma Leuk. 17. Jahrgang, Nr. 11, November 2017, S. 716–722, doi:10.1016/j.clml.2017.06.022, PMID 28709797.
  • JP Bridoux et al.: How I treat monoclonal gammopathy of renal significance (MGRS). In: Blood. 122. Jahrgang, Nr. 22, 9. Oktober 2013, S. 3583–3590, doi:10.1182/blood-2013-05-495929, PMID 24108460.
  • MA Dimopoulos et al.: Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus. In: Blood. 124. Jahrgang, Nr. 9, 17. Juli 2014, S. 1404-11, doi:10.1182/blood-2014-03-565135, PMID 4148763.
  • MA Gertz et al.: Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. In: Am J Hematol. 91. Jahrgang, Nr. 9, 17. August 2016, S. 947-56, doi:10.1002/ajh.24433, PMID 27527836.